fenebrutinib: Clinical Trials

4 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 8 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	8	Completed 4, Terminated 2, Active not recruiting 1, Recruiting 1

Follow fenebrutinib: new trials by email Literature Review of fenebrutinib trials Research Report on fenebrutinib

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS) Fenebrutinib - Relapsing Multiple Sclerosis	Phase 2	Recruiting	Hoffmann-La Roche	12	2025-10-06	2026-10-13
A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) Fenebrutinib, Placebo - Relapsing Multiple Sclerosis	Phase 2	Active not recruiting	Hoffmann-La Roche	109	2022-03-01	2026-09-25
A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study GDC-0853 - Urticaria	Phase 2	Terminated	Genentech, Inc.	31	2018-09-27	2020-09-25
An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus GDC-0853 - Lupus Erythematosus, Systemic	Phase 2	Terminated	Genentech, Inc.	160	2018-01-09	2020-12-19
A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU). GDC-0853, Placebo - Urticaria	Phase 2	Completed	Genentech, Inc.	134	2017-05-26	2020-09-29
A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus GDC-0853, Placebo - Systemic Lupus Erythematosus	Phase 2	Completed	Genentech, Inc.	260	2017-01-19	2024-05-08
A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350 GDC-0853 - Rheumatoid Arthritis	Phase 2	Completed	Genentech, Inc.	496	2016-11-30	2020-08-03
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) GDC-0853, Adalimumab, Folic Acid - Rheumatoid Arthritis	Phase 2	Completed	Genentech, Inc.	578	2016-09-09	2020-06-12

Conditions studied

Arthritis, Rheumatoid (2)  ·  Lupus Erythematosus, Systemic (2)  ·  Urticaria (2)

Sponsors

Genentech, Inc. (6)  ·  Hoffmann-La Roche (2)

Countries

United States (7)  ·  Argentina (5)  ·  Brazil (5)  ·  Mexico (5)  ·  Bulgaria (4)  ·  Colombia (4)  ·  Poland (3)  ·  Serbia (3)  ·  South Korea (3)  ·  Spain (3)  ·  Ukraine (3)  ·  Chile (2)  ·  Germany (2)  ·  Russia (2)  ·  Taiwan (2)

Results publications

PMID 34042314, PMID 40683275

NIH funding

2016 (4), 2017 (1), 2018 (1)